Inactive Instrument

CS MEDICA A/S

Stocks

CSMED

DK0061668225

CS Medica A/S Provides Revenue Guidance for the Fourth Quarter of 2025

Published on 11/30/2025 at 06:27 am EST

S&P Capital IQ

CS MEDICA A/S

-6.15%

CS Medica A/S provided revenue guidance for the fourth quarter of 2025. For the quarter, Management expects higher revenue, continued operational stabilisation, and strengthened regulatory momentum.

Latest news about CS MEDICA A/S

May. 18	CS Medica A/S Revises Revenue Guidance for the Year 2025-2026	CI
Apr. 01	CS Medica A/S Elects Jens Hagelskjær as Board Director	CI
Jan. 21	CS Medica A/S Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
Nov. 30	CS Medica A/S Reports Earnings Results for the Full Year Ended September 30, 2025	CI
Nov. 30	CS Medica A/S Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2025	CI
Nov. 30	CS Medica A/S Provides Revenue Guidance for the Fourth Quarter of 2025	CI
25-05-17	CS Medica A/S Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2025	CI
25-04-16	CS Medica A/S Approves Board Changes	CI
25-03-31	CS Medica A/S Announces Co-CEO Changes	CI
25-03-31	CS Medica A/S Reports Earnings Results for the First Quarter Ended December 31, 2024	CI
25-02-17	CS Medica A/S Announces Board Changes	CI
25-02-17	CS Medica A/S Announces CEO Changes	CI
25-01-09	Ahead of delisting: CS Medica temporarily suspends all non-revenue generating activities	FW
25-01-09	CS Medica has today the last trading day on Spotlight before delisting	FW
25-01-07	CS Medica has signed white label partnership for launch in Italy	FW

Chart CS MEDICA A/S

Duration

Period

CSMED: Dynamic Chart

Company Profile

Employees

Sector

Calendar

Aug. 23 - Earnings release - Q3 2026

More about the company